Iodure (123i) De Sodium Ge Healthcare

Sodium Iodide, the active ingredient in Iodure (123i) De Sodium Ge Healthcare, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is employed for diagnostic imaging of the thyroid and other tissues in patients requiring nuclear medicine studies.

GNH USA supplies Iodure (123i) De Sodium Ge Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring reliable cold‑chain logistics and regulatory compliance for radiopharmaceutical distribution across multiple continents.

Iodure (123i) is a radiopharmaceutical used for nuclear imaging of thyroid and cardiac tissues.

Thyroid imaging: enables visualization of thyroid anatomy and functional activity for diagnosis of nodules, hyperthyroidism, and cancer. Myocardial perfusion imaging: assesses blood flow to the heart muscle to detect ischemia and evaluate coronary artery disease. Whole‑body scintigraphy: detects ectopic or metastatic thyroid tissue throughout the body for comprehensive assessment.

Adverse reactions to Iodure (123i) are generally related to the radiopharmaceutical nature of the preparation and the intravenous route.

Common Side Effects: - Nausea: mild transient feeling of sickness. - Vomiting: occasional brief episodes. - Headache: mild to moderate intensity. - Flushing or warmth sensation. - Metallic taste in the mouth.

Serious or Rare Side Effects: - Allergic reaction: rash, urticaria, or anaphylaxis. - Severe hypotension: sudden drop in blood pressure requiring monitoring. - Cardiac arrhythmia: irregular heart rhythm observed in susceptible patients. - Radiation thyroiditis: inflammation of thyroid tissue after high uptake. - Fetal radiation exposure: potential harm if administered to pregnant women.

When using Iodure (123i), several safety considerations should be observed to minimize risks. - Allergy assessment: confirm no known iodine or radiopharmaceutical hypersensitivity. - Thyroid function test: evaluate baseline thyroid status before administration. - Radiation safety: implement shielding and limit exposure for staff and other patients. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks. - Vital sign monitoring: observe blood pressure and heart rate during and after injection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iodure (123i) may interact with other agents that affect iodine uptake or radiation distribution.

Major Interactions (Avoid): - Concurrent radioactive iodine agents: may cause cumulative radiation dose. - High‑dose thyroid hormone therapy (levothyroxine): reduces sodium‑iodide symporter activity and imaging quality. - Iodinated contrast media: administered within 2–4 weeks can block uptake of I‑123.

Moderate Interactions (Monitor Closely): - Antithyroid drugs (methimazole, propylthiouracil): may diminish tracer accumulation. - Diuretics: alter renal clearance of the radiopharmaceutical. - Beta‑blockers: can mask tachycardia or hypotensive responses during imaging.